CO2017013041A2 - Método para tratar tumores neuroendocrinos donde se sobreexpresan receptores de somatostatatina - Google Patents

Método para tratar tumores neuroendocrinos donde se sobreexpresan receptores de somatostatatina

Info

Publication number
CO2017013041A2
CO2017013041A2 CONC2017/0013041A CO2017013041A CO2017013041A2 CO 2017013041 A2 CO2017013041 A2 CO 2017013041A2 CO 2017013041 A CO2017013041 A CO 2017013041A CO 2017013041 A2 CO2017013041 A2 CO 2017013041A2
Authority
CO
Colombia
Prior art keywords
overexpressed
receptors
somatostatatin
neuroendocrine tumors
therapy
Prior art date
Application number
CONC2017/0013041A
Other languages
English (en)
Inventor
Stefano Buono
Maribel Lopera Sierra
Original Assignee
Advanced Accelerator Applications
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications filed Critical Advanced Accelerator Applications
Publication of CO2017013041A2 publication Critical patent/CO2017013041A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Métodos para tratar cánceres donde se sobreexpresan receptores de somatostatina. Terapia combinada donde se administra una combinación de una terapia con péptidos receptores marcados con radioisótopos (PRRT) y una terapia inmunooncológica (terapia I-O) para tratar tumores neuroendocrinos.
CONC2017/0013041A 2015-06-25 2017-12-19 Método para tratar tumores neuroendocrinos donde se sobreexpresan receptores de somatostatatina CO2017013041A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562176901P 2015-06-25 2015-06-25
PCT/IB2016/001089 WO2016207732A1 (en) 2015-06-25 2016-06-24 Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors

Publications (1)

Publication Number Publication Date
CO2017013041A2 true CO2017013041A2 (es) 2018-03-28

Family

ID=56940095

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0013041A CO2017013041A2 (es) 2015-06-25 2017-12-19 Método para tratar tumores neuroendocrinos donde se sobreexpresan receptores de somatostatatina

Country Status (12)

Country Link
US (2) US20180185524A1 (es)
EP (2) EP3313888A1 (es)
JP (3) JP2018518526A (es)
KR (1) KR20180041623A (es)
CN (1) CN108137690A (es)
CA (1) CA2989266A1 (es)
CO (1) CO2017013041A2 (es)
HK (1) HK1254404A1 (es)
IL (1) IL256543B (es)
MX (1) MX2017016863A (es)
SG (1) SG10201913964QA (es)
WO (1) WO2016207732A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
KR20200088374A (ko) * 2017-11-10 2020-07-22 위스콘신 얼럼나이 리서어치 화운데이션 면역요법에 대한 항-종양 면역 반응을 유도하기 위해 표적화된 방사선요법(trt)을 이용하는 방법
CN112955188A (zh) * 2018-07-25 2021-06-11 先进加速器应用公司 治疗神经内分泌肿瘤的方法
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
EP3693974A1 (en) * 2019-02-07 2020-08-12 Koninklijke Philips N.V. Identifying responsiveness to radio-immuno combination therapy
CN113616818B (zh) * 2020-05-06 2023-04-25 北京大学 一种用于肿瘤的靶向放射与免疫联合治疗的药物组合物
TW202214674A (zh) * 2020-06-29 2022-04-16 大陸商北京拓界生物醫藥科技有限公司 一種放射性核種標記化合物及其應用
CN111840585B (zh) * 2020-07-20 2022-05-03 厦门大学 一种用于肿瘤免疫治疗的药物组合
CA3190855A1 (en) 2020-08-27 2022-03-03 Joe Mccann Radiopharmaceutical and methods
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
WO2023084445A1 (en) 2021-11-12 2023-05-19 Novartis Ag Combination therapy for treating lung cancer
WO2023208341A1 (en) 2022-04-27 2023-11-02 ITM Isotope Technologies Munich SE Combination treatment of small-cell lung cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
EP2456790A1 (en) * 2009-07-20 2012-05-30 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US9150656B2 (en) * 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
CN104491890A (zh) * 2014-11-21 2015-04-08 北京肿瘤医院 放射性核素标记的新型生长抑素类似物分子探针及其应用

Also Published As

Publication number Publication date
US20180185524A1 (en) 2018-07-05
EP4286008A3 (en) 2024-02-28
CA2989266A1 (en) 2016-12-29
EP3313888A1 (en) 2018-05-02
HK1254404A1 (zh) 2019-07-19
IL256543B (en) 2022-01-01
JP2020040992A (ja) 2020-03-19
WO2016207732A1 (en) 2016-12-29
EP4286008A2 (en) 2023-12-06
KR20180041623A (ko) 2018-04-24
JP2023002792A (ja) 2023-01-10
IL256543A (en) 2018-02-28
JP2018518526A (ja) 2018-07-12
US20220143227A1 (en) 2022-05-12
MX2017016863A (es) 2018-09-06
SG10201913964QA (en) 2020-03-30
CN108137690A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
CO2017013041A2 (es) Método para tratar tumores neuroendocrinos donde se sobreexpresan receptores de somatostatatina
CL2020001691A1 (es) Exosomas para inmunooncología y terapia antiinflamatoria.
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
PH12019501959A1 (en) Therapeutic rna
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
CY1123611T1 (el) Μεθοδος για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
MX2016007282A (es) Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.
DOP2018000138A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
EA201691568A1 (ru) Твердые фармацевтические композиции антагонистов рецепторов андрогенов
MX2016002051A (es) Metodos y kits para la subtipificacion molecular de tumores.
CY1121722T1 (el) Μεθοδοι για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης
SV2019005822A (es) Metodos para tratar el cáncer de próstata
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
CL2017001310A1 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
UY36286A (es) Tratamientos médicos basados en anamorelina
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2017016346A (es) Metodos de tratamiento con taselisib.
UY35823A (es) Profármacos de antagonista de nmda
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
ES1206437Y (es) Parche autoadhesivo para estimulación del clitoris
CL2019000214A1 (es) Métodos para tratar el cáncer de próstata.
EA201990411A1 (ru) Способы лечения рака предстательной железы